Juniper Biosciences Secures FDA Breakthrough Designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Juniper Biosciences’ JBS-003 (18F-fluoromisonidazole, or FMISO) for identifying tumour hypoxia in patients with HPV-positive oropharyngeal carcinoma (OPC).

JBS-003 is a hypoxia tracer licensed from Memorial Sloan Kettering Cancer Center (MSK). 

It uses molecular imaging to identify oxygen-deprived areas in tumours, which can indicate resistance to radiation therapy and help guide treatment decisions.

The technology is being evaluated as a tool for personalised radiation de-escalation. 

Research suggests that about 80% of patients with HPV-positive OPC have non-hypoxic tumours and may be suitable for a reduced radiation dose of 30 Gray, compared with the standard 70 Gray regimen.

JBS-003 is being studied in a Phase 3 randomised, double-blind trial (NCT06563479). Patients undergo FMISO imaging during treatment. 

Those with non-hypoxic tumours may receive the reduced radiation dose, while patients with hypoxic tumours continue with standard treatment.

The Breakthrough Therapy Designation provides Juniper Biosciences with enhanced engagement with the FDA during development and may support a more efficient regulatory pathway. 

The Phase 3 trial is expected to reach primary completion in early 2028